Scancell (LON:SCLP) Shares Down 3.1% – Here’s What Happened

Scancell Holdings plc (LON:SCLP)’s stock price fell 3.1% on Friday . The company traded as low as GBX 11.63 and last traded at GBX 12.50. 444,921 shares traded hands during trading, a decline of 74% from the average session volume of 1,685,915 shares. The stock had previously closed at GBX 12.90.

Scancell Stock Performance

The stock’s fifty day simple moving average is GBX 12.88 and its two-hundred day simple moving average is GBX 10.86. The company has a market cap of £121.78 million, a price-to-earnings ratio of -21.34 and a beta of 0.33. The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56.

Scancell (LON:SCLP) last released its quarterly earnings data on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. Scancell had a positive return on equity of 90.29% and a negative net margin of 116.98%. Equities research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.